| |
PCV13 (A)
|
PHiD-CV (B)
|
Difference (B−A)
|
|---|
|
Health outcomes
|
|
IPD cases (acute episode)
|
99
|
108
|
9
|
|
All-cause pneumonia cases (acute episode)
|
19,714
|
19,754
|
40
|
|
AOM cases (acute episode)
|
135,206
|
130,783
|
−4424
|
|
Deaths due to IPD/pneumonia
|
17
|
17
|
0
|
|
Costs
|
|
Vaccination
|
NTD 926 465 468
|
NTD 926 465 418
|
− NTD 50
|
|
Acute episode
|
|
IPD
|
NTD 7 341 171
|
NTD 7 992 670
|
NTD 651 499
|
|
All-cause pneumonia
|
NTD 352 720 474
|
NTD 353 278 362
|
NTD 557 957
|
|
AOM
|
NTD 189 117 177
|
NTD 178 291 679
|
− NTD 10 825 498
|
|
Total
|
|
Undiscounted
|
NTD 1 475 644 291
|
NTD 1 466 028 130
|
- NTD 9 616 161
|
|
Discounted
|
NTD 1 392 017 676
|
NTD 1 383 217 323
|
- NTD 8 800 353
|
- AOM acute otitis media, IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, NTD new Taiwan dollar
